Sparsity-based Magnetic Resonance Imaging of Cardiac Arrhythmias

NCT ID: NCT02741180

Last Updated: 2025-06-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

NA

Total Enrollment

135 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-29

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to improve the quality of Magnetic Resonance Imaging in patients with heart arrhythmia. Investigators will recruit 105 patients with arrhythmia and 30 control volunteers over 3 years and will use two arrhythmia-tolerant imaging methods for diagnosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the proposed research, investigators will extend conventional cardiac magnetic resonance methods to enable the creation of high-quality cine CMR images in the presence of multiple kinds of arrhythmia. Two arrhythmia-tolerant imaging methods will be adopted, which are particularly useful in arrhythmia: 1) 3D imaging, which is useful for many purposes, including "road mapping" of electrophysiology (EP) procedures, and 2) late gadolinium enhancement (LGE), which is useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrythmias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Arrhythmias

Group Type OTHER

3D Imaging

Intervention Type OTHER

"roadmapping" of electrophysiology (EP) procedures

Late Gadolinium Enhancement (LGE)

Intervention Type OTHER

useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.

Healthy Control

Group Type OTHER

3D Imaging

Intervention Type OTHER

"roadmapping" of electrophysiology (EP) procedures

Late Gadolinium Enhancement (LGE)

Intervention Type OTHER

useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3D Imaging

"roadmapping" of electrophysiology (EP) procedures

Intervention Type OTHER

Late Gadolinium Enhancement (LGE)

useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with heart arrhythmia scheduled for routine clinical MRI examinations).
* Patients scheduled for routine clinical MRI examinations who do not have a specific known diagnosis of arrhythmia, but who may be found to have image degradation due to arrhythmia during the CMR examination.


* No history of heart arrhythmia.

Exclusion Criteria

* Hemodynamic instability.
* Contraindications for MRI examinations (e.g., pacemakers or ferromagnetic vascular clips).
* History of prior cardiovascular disease or significant risk factors:

* Diabetes, hypertension, smoking, and hyperlipidemia, etc.
Minimum Eligible Age

10 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NYU Langone Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Leon Axel, MD

Role: PRINCIPAL_INVESTIGATOR

New York University Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York University School of Medicine

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15-00116

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Edema and Fibrosis CMR Imaging in Cardiomyopathy
NCT03534726 ACTIVE_NOT_RECRUITING
HCMR Re-Imaging Study
NCT07054073 NOT_YET_RECRUITING
Radiation-Free Heart Catheterization Using MRI
NCT02739087 ACTIVE_NOT_RECRUITING NA